Testing Items for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

PART OF:
Kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust
Made:
2020

Postal bag containing testing items from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.

Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Details

Category:
Public Health & Hygiene
Object Number:
2022-1441/3
Materials:
cardboard, paper (fibre product), textile and plastic (unidentified)
type:
test kit (medical)
credit:
Novavax, Inc

Parts

Postal Bag from Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Postal Bag from Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Grey rapisac postal bag for kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.


Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Materials:
plastic (unidentified)
Object Number:
2022-1441/3/1
type:
bag - container
Postage Box for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Postage Box for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Cardboard postage box for Covid 19 test kit, from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.


Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Materials:
cardboard
Object Number:
2022-1441/3/2
type:
box - container
Covid-19 Home Test Instructions Leaflet for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Covid-19 Home Test Instructions Leaflet for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Covid-19 home test instructions leaflet from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.


Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Materials:
paper (fibre product)
Object Number:
2022-1441/3/3
type:
instructions
Swab Sampler for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Swab Sampler for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Sealed disposable oropharyngeal swab sampler from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.


Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Materials:
plastic (unidentified)
Object Number:
2022-1441/3/4
type:
swab
Empty Tube from Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Empty Tube from Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Empty tube from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.


Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Materials:
plastic (unidentified) and paper (fibre product)
Object Number:
2022-1441/3/5
type:
tubes
Absorbent Pad from Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Absorbent Pad from Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Rectangular absorbent pad from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.


Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Materials:
textile
Object Number:
2022-1441/3/6
type:
absorber
Security Seal from Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Security Seal from Phase 3 Novavax 2019nCoV-302 Vaccine Trial

MDXsol security seal from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.


Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Materials:
plastic (unidentified)
Object Number:
2022-1441/3/7
type:
seals
Plastic Bag for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Plastic Bag for Phase 3 Novavax 2019nCoV-302 Vaccine Trial

Barcoded plastic bag for holding used vial and absorbent sheet, from kit for phase 3 Novavax 2019nCoV-302 vaccine trial at Stockport NHS Foundation Trust.


Launched in September 2020, the phase 3 trial of Novavax’s vaccine was the largest ever double blind placebo controlled trial to be undertaken in the United Kingdom. This meant that the researchers or participants did not know what injection people received. Half of the participants were given the active vaccine and the other half, an inactive solution.15,000 people were involved from 35 research sites. The highest recruiting region was Greater Manchester with 1240 volunteers from Stockport NHS Foundation Trust and the Northern Care Alliance NHS Group. This kit was used with volunteers to monitor them during the trial and represents the crucial role volunteers play in the process.

Phase 3 trial results showed an overall 89.7% efficacy rate including against alpha and beta variants of the virus. Earlier clinical trials were carried out in Australia, United States and South Africa. All volunteers who received placebo solution are to be offered the active vaccine.

Materials:
plastic (unidentified)
Object Number:
2022-1441/3/8
type:
bag - container